Cushing's Syndrome Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments - Product Image

Cushing's Syndrome Therapeutics - Pipeline Analysis 2017, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

  • ID: 4451355
  • Report
  • Region: Global
  • 70 pages
  • P&S Market Research
1 of 4
Cushing’s syndrome currently exhibits a growing pipeline with 13 drug candidates.

Cushing’s syndrome therapeutics pipeline in 2017

The study analyzed that the Cushing’s syndrome therapeutics pipeline comprises of approximately 13 drug candidates.

Insights on pipeline segments

Orphan drug designations from the European Medicines Agency (EMA) is the one of the drivers for the development of pipeline drugs of Cushing’s syndrome. Majority of the pipeline drug candidates are being developed using the oral route of administration. Osilodrostat which is being developed by the Novartis AG is in the Phase III stage of development for the treatment of Cushing’s syndrome.

Positive clinical trial results propelling the growth of the pipeline

The existing drugs that are developed by the various pharmaceutical companies for the treatment of the disease have demonstrated positive clinical trial results, which in-turn is supporting their further development. For instance, Osilodrostat which is being developed by the Novartis AG demonstrated efficacy and well tolerated in the Phase II proof of concept study for the treatment of the Cushing’s syndrome.

Specific Targeted Therapy to Provide Various Opportunities

The drug development process involves specific target such as steroid 11-beta-hydroxylase, which is the probable mechanism of action for the treatment of Cushing’s syndrome. Thus, this specific targeted therapy provides opportunities to the companies for better and targeted drug development. Some of the players developing drugs for the treatment of Cushing’s syndrome include Novartis AG, AstraZeneca Plc, Cyclacel Pharmaceuticals, Inc., and Angion Biomedica Corp.

Cushing’s Syndrome Therapeutics Pipeline Analysis
  • By Phase
  • By Molecule Type
  • By Route of Administration
  • By Company
READ MORE
Note: Product cover images may vary from those shown
2 of 4
Chapter 1. Research Background
1.1 Research Objectives
1.2 Definition
1.3 Research Scope
1.3.1 Pipeline Analysis by Phase
1.3.2 Pipeline Analysis by Molecule Type
1.3.3 Pipeline Analysis by Route of Administration
1.4 Key Stakeholders

Chapter 2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.2.1 Breakdown of Primary Research Respondents
2.2.1.1 By industry participant
2.2.1.2 By company type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook
4.1 Cushing’s Syndrome Disease Overview
4.1.1 Signs and Symptoms
4.1.2 Pathophysiology
4.1.3 Diagnosis
4.1.4 Treatment
4.1.5 Epidemiology
4.2 Key Drivers
4.2.1 Driver 1
4.2.2 Driver 2
4.3 Key Barriers
4.3.1 Barrier 1
4.4 Cushing’s Syndrome Pipeline Analysis
4.4.1 Pipeline Analysis by Phase
4.4.2 Pipeline Analysis by Molecule Type
4.4.3 Pipeline Analysis by Route of Administration
4.4.4 Pipeline Analysis by Company

Chapter 5. Cushing’s Syndrome Therapeutics Pipeline Analysis by Phase
5.1 Phase III
5.1.1 Osilodrostat
5.1.1.1 Clinical trials
5.1.2.1 Clinical trials
5.1.2.2 Designation
5.2 Phase II
5.2.1 ATR-101
5.2.1.1 Clinical trials
5.2.2.1 Clinical trials
5.2.4.1 Clinical trials
5.3 Pre-Clinical
5.3.1 AP 102
5.3.1.1 Pre-Clinical trials
5.3.2.1 Pre-Clinical results
5.4 Discovery
5.4.1 Orphan Nuclear Receptor Antagonist - Orphagen Pharmaceuticals Inc.
5.4.3.1 Strategic development
5.5 Unknown

Chapter 6. Clinical Trials Analysis
6.1 Clinical Trials, by Region
6.2 Clinical Trials, by Trial Status

Chapter 7. Competitive Landscape
7.1 Key Players Benchmarking for Cushing’s syndrome Therapeutics Pipeline
7.2 SWOT Analysis of Cushing’s Syndrome Therapeutics Pipeline
7.2.1 Strengths
7.2.2 Weaknesses
7.2.3 Opportunities
7.2.4 Threats

Chapter 8. Company Profiles
8.1 Novartis AG
8.1.1 Business Overview
8.1.2 Product & Service Offerings
8.2 AstraZeneca plc
8.2.1 Business Overview
8.2.2 Product & Service Offerings

Chapter 9. Appendix
9.1 Abbreviations
9.2 Related Reports
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AstraZeneca plc
  • Novartis AG
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll